PE20171308A1 - Forma de dosificacion que incluye una solucion solida de drogas amorfas - Google Patents

Forma de dosificacion que incluye una solucion solida de drogas amorfas

Info

Publication number
PE20171308A1
PE20171308A1 PE2017001187A PE2017001187A PE20171308A1 PE 20171308 A1 PE20171308 A1 PE 20171308A1 PE 2017001187 A PE2017001187 A PE 2017001187A PE 2017001187 A PE2017001187 A PE 2017001187A PE 20171308 A1 PE20171308 A1 PE 20171308A1
Authority
PE
Peru
Prior art keywords
dosage form
solid amorphous
drug solution
form including
amorphous drug
Prior art date
Application number
PE2017001187A
Other languages
English (en)
Inventor
Escobar Maria Del Pilar Noriega
Laura Restrepo Uribe
Enrique Sanjuan Mejia Marco
Carlos Arturo Altamar
Blanco Claudia Andrea Silva
Original Assignee
Procaps SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56285892&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20171308(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Procaps SAS filed Critical Procaps SAS
Publication of PE20171308A1 publication Critical patent/PE20171308A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7007—Drug-containing films, membranes or sheets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Furan Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Cephalosporin Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrane Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Epoxy Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pyrrole Compounds (AREA)
  • Steroid Compounds (AREA)
  • Indole Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Abstract

SE REFIERE A UN METODO PARA PREPARAR UNA FORMA DE DOSIFICACION FARMACEUTICA QUE COMPRENDE: A) PREPARAR POR EXTRUSION EN ESTADO FUNDIDO O AMASAR UNA SOLUCION SOLIDA AMORFA DE UNO O MAS INGREDIENTES ACTIVOS TALES COMO ACICLOVIR, AZITROMICINA, CEFUROXIMA, CLARITROMICINA, ACIDO FOLICO, DEXAMETASONA, FUROSEMIDA, MELOXICAM, ENTRE OTROS; Y B) COLOCAR DICHA DISOLUCION AMORFA SOLIDA DE DICHO INGREDIENTE ACTIVO EN UNA FORMA DE DOSIFICACION ADECUADA; DONDE LA SOLUCION SOLIDA AMORFA INCLUYE UNO O MAS POLIMEROS FARMACEUTICAMENTE ACEPTABLES O NUTRACEUTICOS ACEPTABLES PARA ALIMENTOS, Y SE PROCESA EN GRANULOS O MICROGRANULOS. DICHO METODO ES UTIL PARA DIRIGIR UN PERFIL DE LIBERACION ESPECIFICO
PE2017001187A 2015-01-06 2015-09-10 Forma de dosificacion que incluye una solucion solida de drogas amorfas PE20171308A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562100117P 2015-01-06 2015-01-06
US14/849,571 US20160193151A1 (en) 2015-01-06 2015-09-09 Dosage form incorporating an amorphous drug solid solution

Publications (1)

Publication Number Publication Date
PE20171308A1 true PE20171308A1 (es) 2017-09-05

Family

ID=56285892

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2017001187A PE20171308A1 (es) 2015-01-06 2015-09-10 Forma de dosificacion que incluye una solucion solida de drogas amorfas

Country Status (13)

Country Link
US (1) US20160193151A1 (es)
EP (1) EP3242650A4 (es)
JP (2) JP2018507180A (es)
KR (1) KR20180102484A (es)
BR (1) BR112017014675A2 (es)
CA (1) CA2973218A1 (es)
CO (1) CO2017006788A2 (es)
CR (1) CR20170361A (es)
DO (1) DOP2017000162A (es)
EC (1) ECSP17046608A (es)
MX (1) MX2017008939A (es)
PE (1) PE20171308A1 (es)
WO (1) WO2016111725A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2619840C1 (ru) * 2016-09-21 2017-05-18 Общество с ограниченной ответственностью "Изварино Фарма" Фармацевтическая композиция для лечения ВИЧ-инфекции
JP6757351B2 (ja) * 2017-04-28 2020-09-16 日東電工株式会社 経皮吸収型製剤
US20200206139A1 (en) * 2017-09-11 2020-07-02 Board Of Regents, The University Of Texas System Compositions for the improved delivery of drugs
US20200405643A1 (en) * 2017-09-11 2020-12-31 Board Of Regents, The University Of Texas System Drug compositions containing porous carriers made by thermal or fusion-based processes
WO2019113084A1 (en) 2017-12-05 2019-06-13 Sunovion Pharmaceuticals Inc. Crystal forms and production methods thereof
AU2018379992B2 (en) 2017-12-05 2022-07-21 Sunovion Pharmaceuticals Inc. Nonracemic mixtures and uses thereof
WO2020072008A1 (en) * 2018-10-04 2020-04-09 Deva Holding Anonim Sirketi Novel solid dispersions of selinexor
JP2022535893A (ja) 2019-06-04 2022-08-10 サノビオン ファーマシューティカルズ インク 放出調節製剤およびその使用
CN110585156B (zh) * 2019-10-24 2021-09-28 中国人民解放军军事科学院军事医学研究院 一种对乙酰氨基酚缓释制剂及其3d打印制备方法
WO2021188517A1 (en) * 2020-03-17 2021-09-23 Rutgers, The State University Of New Jersey Continuous melt-coating of active pharmaceutical ingredients using surfactants for dissolution enhancement
KR102594715B1 (ko) * 2020-04-17 2023-10-27 영남대학교 산학협력단 경구 생체 이용률이 증가된 니클로사마이드 함유 고체분산체 및 이의 제조방법
EP4236953A1 (en) * 2020-10-27 2023-09-06 ISP Investments LLC Method and system for predicting properties of amorphous solid dispersions using machine learning
GB2607554B (en) * 2021-03-04 2024-04-10 Reckitt Benckiser Health Ltd Novel composition
US20220296529A1 (en) * 2021-03-17 2022-09-22 Carlos Salazar Altamar Pre-filling system to eliminate bubbles inside capsules having a solid dosage forms within said capsules
CN114073679A (zh) * 2021-10-13 2022-02-22 广州汇元医药科技有限公司 一种塞来昔布组合物及其制备方法和应用
KR102684499B1 (ko) * 2022-01-12 2024-07-11 충남대학교산학협력단 메벤다졸 함유 고체 분산체, 이를 포함하는 약제학적 조성물 및 이의 제조방법
WO2023145871A1 (ja) * 2022-01-31 2023-08-03 住友精化株式会社 製剤用組成物の製造方法及び製剤の製造方法
WO2023145869A1 (ja) * 2022-01-31 2023-08-03 住友精化株式会社 製剤用組成物の製造方法及び製剤の製造方法
WO2024092237A1 (en) * 2022-10-28 2024-05-02 Board Of Regents, The University Of Texas System Continuous mid-air 3-dimensional printing for pharmaceutical dosage forms

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69927177T2 (de) * 1998-12-16 2006-06-08 Aventis Pharmaceuticals Inc. In biologisch abbaubare polymere eingekapselter serotoninrezeptor-antagonist und deren herstellungsverfahren
CA2612864A1 (en) * 2005-07-05 2007-01-11 Abbott Gmbh & Co. Kg Composition and dosage form comprising a solid or semi-solid matrix
WO2008037809A1 (en) * 2006-09-29 2008-04-03 Abbott Gmbh & Co. Kg Transmucosal administration of fibrate compounds and delivery system therefor
JP5654002B2 (ja) * 2009-05-13 2015-01-14 ビーエーエスエフ ソシエタス・ヨーロピアＢａｓｆ Ｓｅ ポリエーテルに基づくコポリマーを微水溶性ポリマーと組み合わせて含む固体医薬調製物
CN102655857A (zh) * 2009-09-18 2012-09-05 巴斯夫欧洲公司 含有基于聚醚的两亲性共聚物与亲水聚合物组合的速溶性固体药物制剂
WO2011039675A2 (en) * 2009-09-30 2011-04-07 Pfizer Inc. Latrepirdine transdermal therapeutic dosage forms
JP2013511565A (ja) * 2009-11-24 2013-04-04 ビーエーエスエフ ソシエタス・ヨーロピア フィルム様医薬剤形
US9594073B2 (en) * 2010-02-18 2017-03-14 Abbvie Deutschland Gmbh & Co Kg Test solvent for evaluating the compatibility of biologically active substances and graft copolymers
NZ605440A (en) * 2010-06-10 2014-05-30 Abbvie Bahamas Ltd Solid compositions comprising an hcv inhibitor
RU2489445C2 (ru) * 2011-04-13 2013-08-10 Владимир Дмитриевич Артемьев Способ получения из топинамбура инулинсодержащего раствора, способ получения инулина и способ получения фруктоолигосахаридов на основе этого раствора

Also Published As

Publication number Publication date
CA2973218A1 (en) 2016-07-14
JP2018507180A (ja) 2018-03-15
MX2017008939A (es) 2018-11-09
EP3242650A1 (en) 2017-11-15
WO2016111725A1 (en) 2016-07-14
US20160193151A1 (en) 2016-07-07
JP2021059540A (ja) 2021-04-15
DOP2017000162A (es) 2018-11-15
CR20170361A (es) 2018-01-25
CO2017006788A2 (es) 2017-07-19
BR112017014675A2 (pt) 2018-03-13
EP3242650A4 (en) 2018-08-01
ECSP17046608A (es) 2017-07-31
KR20180102484A (ko) 2018-09-17

Similar Documents

Publication Publication Date Title
PE20171308A1 (es) Forma de dosificacion que incluye una solucion solida de drogas amorfas
CO2018003558A2 (es) Método de cristalización y biodisponibilidad
BR112012023324B8 (pt) processo de preparação de uma forma de dosagem multifásica liofilizada de dissolução rápida
EP3206706A4 (en) Stable injectable composition of pharmaceutically active agents and process for its preparation
PL3003285T3 (pl) Stała farmaceutyczna postać dawkowania do uwalniania co najmniej dwóch substancji czynnych w jamie ustnej
AU2015242791A1 (en) Drug Delivery Enhancer Comprising Substance For Activating Lysophospholipid Receptors
EA201690679A1 (ru) Стабильная фармацевтическая композиция, содержащая амлодипин и валсартан
AR105203A1 (es) Formulación oral sólida que contiene irinotecán y método de preparación de la misma
DK3168214T3 (da) Substituerede 2-thioxo-imidazolidin-4-oner og spiro- analoger deraf, aktiv anti-canceringrediens, farmaceutisk sammensætning, medicinpræparat, fremgangsmåde til behandling af prostatacancer
EA201501164A1 (ru) Твердая фармацевтическая лекарственная форма
CR20140358A (es) Sistema para la administración de fármacos
BR112015010271A8 (pt) produto de comicronização, processo para o preparo de um produto de comicronização, composição farmacêutica e seus usos
AR091621A1 (es) Formas de presentacion farmaceuticas que contienen 5-cloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4-morfolinil)-fenil]-1,3-oxazolidin-5-il}-metil)-2-tiofen-carboxamida
MX2016012319A (es) Formulaciones antihelminticas veterinarias estables.
EP3311809A4 (en) USE OF A PHARMACEUTICAL COMPOSITION IN THE PREPARATION OF A MEDICAMENT FOR PROMOTING CHONDROCYTE PRODUCTION
EP3697381C0 (en) OPIATE RECEPTOR AGONIST PHARMACEUTICAL FORMULATIONS, METHOD OF PREPARATION AND THERAPEUTIC USES THEREOF
UY36474A (es) Método para producir liposomas que contienen un ingrediente farmacéutico activo
MX348595B (es) Composicion farmaceutica con agentes antiinflamatorios y proceso de produccion.
CO2017006222A2 (es) Composición farmacéutica para el tratamiento de enfermedades gastrointestinales
NZ702849A (en) Genotype- or phenotype-based drug formulation
AR093922A1 (es) Composicion farmaceutica que contiene telmisartan
PH12016502540A1 (en) Pharmaceutical dosage forms
CL2017002470A1 (es) Proceso para obtener mezclas de polvo seco
DOP2016000078A (es) Formas de dosificación farmacéutica que comprenden 1-[6-(morfolin-4-il)pirimidin-4-il]-4-(1h-1,2,3-triazol-1-il)-1h-pirazol-5-olato de sodio
BR112015003761A2 (pt) composto, composição farmacêutica, forma unitária de dosagem, método para administrar um agente biologicamente ativo e método para preparar uma composição